Kinases have emerged in recent years as promising targets for therapeutic intervention, unsurprisingly, as mutations in kinase domains have been linked to an array of human disorders—most notably cancers. With known kinases sharing a high degree of homology it is imperative for investigators to mine the depths of the human kinome, to identify novel inhibitors with potent and selective activity. Dr. Gary Johnson’s laboratory has been focused on “understanding the kinase protein class by identifying the activation or inhibition of kinases due to the presence of perturbation and compare those states in known signaling networks.” The video below is part of the IDG consortium’s flash talk series in which Dr. Johnson presented some recent data about his team’s study of the human kinome.
